{"id":649920,"date":"2023-05-01T17:56:02","date_gmt":"2023-05-01T17:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=649920"},"modified":"2023-05-01T17:56:02","modified_gmt":"2023-05-01T17:56:02","slug":"chemotherapy-induced-anemia-market-analysis-market-size-share-epidemiology-leading-companies-companies-fibrogen-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chemotherapy-induced-anemia-market-analysis-market-size-share-epidemiology-leading-companies-companies-fibrogen-and-others_649920.html","title":{"rendered":"Chemotherapy Induced Anemia Market Analysis, Market Size & Share, Epidemiology, Leading Companies | Companies – FibroGen, and others"},"content":{"rendered":"
\n
\"Chemotherapy<\/a><\/div>\n
\n
Chemotherapy-Induced Anemia Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Chemotherapy Induced Anemia – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on”Chemotherapy Induced Anemia – Market Insights, Epidemiology, and Market Forecast-2032”.<\/strong><\/p>\n

DelveInsight’s “Chemotherapy Induced Anemia – Market Insights, Epidemiology, and Market Forecast-2032<\/a><\/strong>″ report delivers an in-depth understanding of the Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the  Chemotherapy Induced Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Chemotherapy Induced Anemia Market<\/a> Report:<\/strong><\/p>\n

    \n
  1. The European Cancer Anaemia Survey (ECAS) was conducted to prospectively evaluate the prevalence, incidence and treatment of anemia in European cancer patients, including the relationship of mild, moderate and severe anemia to performance status. The incidence of anaemia in a well-defined incidence population was 53.7% overall and 62.7% for patients who received chemotherapy. <\/li>\n
  2. According to a study, The most common comorbid conditions before starting chemotherapy were hypertension (46.4%), diabetes (22.6%), and renal disease (11.2%). The most common regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)\/rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) (58.7%), followed by bendamustine with or without rituximab (11%).<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. Chemotherapy Induced Anemia market report covers a descriptive overview and comprehensive insight of the Chemotherapy Induced Anemia epidemiology and Chemotherapy Induced Anemia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. The Chemotherapy Induced Anemia market report provides insights on the current and emerging therapies.<\/li>\n
    3. Chemotherapy Induced Anemia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n
    4. The Chemotherapy Induced Anemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chemotherapy Induced Anemia market.<\/li>\n<\/ol>\n

      Got queries? Click here to know more about Chemotherapy Induced Anemia Market Landscape<\/a>.<\/strong><\/p>\n

      Chemotherapy Induced Anemia Overview<\/strong><\/p>\n

      Anemia is common in patients with cancer and is a frequent complication of myelosuppressive chemotherapy. The severity of anemia depends on the extent of disease and the intensity of treatment. Repeated cycles of chemotherapy may impair erythropoiesis cumulatively. The symptoms of anemia can reduce QOL.<\/p>\n

      The key players involved in the Chemotherapy Induced Anemia market<\/a>:<\/strong><\/p>\n